0001213900-24-023188.txt : 20240318 0001213900-24-023188.hdr.sgml : 20240318 20240318063040 ACCESSION NUMBER: 0001213900-24-023188 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240315 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virpax Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001708331 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821510982 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40064 FILM NUMBER: 24756870 BUSINESS ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 BUSINESS PHONE: 610-727-4597 MAIL ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 FORMER COMPANY: FORMER CONFORMED NAME: Virpax Pharmaceuticals Inc. DATE OF NAME CHANGE: 20170602 8-K 1 ea0201947-8k_virpaxphrm.htm CURRENT REPORT
false 0001708331 0001708331 2024-03-15 2024-03-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 15, 2024

 

Virpax Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40064   82-1510982
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of principal executive offices, including zip code)

 

(610) 727-4597

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Trading Symbol   Name of Each Exchange on which Registered
Common Stock, par value $0.00001 per share   VRPX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

 

On March 15, 2024, Virpax Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that for the last 10 consecutive business days, from March 1, through 14, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

 

Item 8.01 Other Information

 

On March 14, 2024, the United States Bankruptcy Court for the Southern District Of Texas for entry of an order (this “Order”) entered an order approving the settlement between Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., and the Company, as set forth on the Settlement Agreement and Mutual Release filed as Exhibit 10.1 to this Current Report on Form 8-K (“Agreement”).

 

The foregoing summary is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 and incorporated herein by this reference.

 

Item 9.01. Financial Statements and Exhibits. 

 

(d) Exhibits.

 

Exhibit
Number		   Exhibit Description
     
10.1   Settlement Agreement and Mutual Releasee between Virpax Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on March 1, 2024 (File No. 001-40064)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIRPAX PHARMACEUTICALS, INC.
     
Dated: March 18, 2024 By: /s/ Vinay Shah 
    Vinay Shah                    
    Chief Financial Officer 

 

 

2

 

 

 EX-101.SCH 2 vrpx-20240315.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vrpx-20240315_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 vrpx-20240315_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 15, 2024
Entity File Number 001-40064
Entity Registrant Name Virpax Pharmaceuticals, Inc.
Entity Central Index Key 0001708331
Entity Tax Identification Number 82-1510982
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-4597
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol VRPX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://virpaxpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0201947-8k_virpaxphrm.htm vrpx-20240315.xsd vrpx-20240315_lab.xml vrpx-20240315_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0201947-8k_virpaxphrm.htm": { "nsprefix": "VRPX", "nsuri": "http://virpaxpharma.com/20240315", "dts": { "inline": { "local": [ "ea0201947-8k_virpaxphrm.htm" ] }, "schema": { "local": [ "vrpx-20240315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "vrpx-20240315_lab.xml" ] }, "presentationLink": { "local": [ "vrpx-20240315_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://virpaxpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201947-8k_virpaxphrm.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0201947-8k_virpaxphrm.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://virpaxpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-24-023188-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-023188-xbrl.zip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end XML 16 ea0201947-8k_virpaxphrm_htm.xml IDEA: XBRL DOCUMENT 0001708331 2024-03-15 2024-03-15 iso4217:USD shares iso4217:USD shares false 0001708331 8-K 2024-03-15 Virpax Pharmaceuticals, Inc. DE 001-40064 82-1510982 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-4597 false false false false Common Stock, par value $0.00001 per share VRPX NASDAQ true false